Baudax Bio (BXRX) Misses Q3 EPS by 5c; Cash and Cash Equivalents of $24.9M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Oil rises on Iran war stalemate; near-term potential for further gains seen limited
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
Baudax Bio Reports Third Quarter 2021 Financial Results and Business Highlights
November 4, 2021 7:00 AM EDTANJESO® Revenue Up 40% in Q3 2021 over Q2 2021 and Up Over 300% in Q3 2021 over Q3 2020
Solid Growth in End User Demand Units, September 2021 Strongest Month Launch-to-Date, Indicating Growing Adoption of ANJESO
Neuromuscular Blocking Agent BX1000 Completes Clinical Phase of Dose Escalation Study
Management to Host Investor Conference Call and Webcast Today at 8:00 a.m. ET
MALVERN, Pa., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Baudax Bio, Inc. (NASDAQ: BXRX) (the Company), a pharmaceutical company focused on commercializing... More
